Pharmacological and histochemical distinctions between molecularly defined sarcolemmal K(ATP) channels and native cardiac mitochondrial K(ATP) channels

Hai Hu, Toshiaki Sato, Jegatheesan Seharaseyon, Yongge Liu, David C. Johns, Brian O'Rourke, Eduardo Marbán

Research output: Contribution to journalArticle

Abstract

A variety of direct and indirect techniques have revealed the existence of ATP-sensitive potassium (K(ATP)) channels in the inner membranes of mitochondria. The molecular identity of these mitochondrial K(ATP) (mitoK(ATP)) channels remains unclear. We used a pharmacological approach to distinguish mitoK(ATP) channels from classical, molecularly defined cardiac sarcolemmal K(ATP) (surfaceK(ATP)) channels encoded by the sulfonylurea receptor SUR2A and the pore-forming subunit K(ir)6.2. SUR2A and K(ir)6.2 were expressed in human embryonic kidney (HEK)293 cells, and their activities were measured by patch-clamp recordings of membrane current. SurfaceK(ATP) channels are activated potently by 100 μM pinacidil but only weakly by 100 μM diazoxide; in addition, they are blocked by 10 μM glibenclamide, but are insensitive to 500 μM 5-hydroxydecanoate. This pharmacology, which was confirmed with patch-clamp recordings in intact rabbit ventricular myocytes contrasts with that of mitoK(ATP) channels as indexed by flavoprotein oxidation. MitoK(ATP) channels in myocytes are activated equally by 100 μM diazoxide and 100 μM pinacidil. In contrast to its lack of effect on surfaceK(ATP) channels, 5-hydroxydecanoate is an effective blocker of mitoK(ATP) channels. Glibenclamide's effects on mitoK(ATP) channels are difficult to assess, because it independently activates flavoprotein fluorescence, consistent with a previously described primary uncoupling effect. Confocal imaging of the subcellular distribution of expressed fluorescent K(ir)6.2 in HEK cells and in myocytes revealed no targeting of mitochondrial membranes. The differences in drug sensitivity and subcellular localization indicate that mitoK(ATP) channels are distinct from surface N(ATP) channels at a molecular level.

Original languageEnglish (US)
Pages (from-to)1000-1005
Number of pages6
JournalMolecular Pharmacology
Volume55
Issue number6
StatePublished - 1999

Fingerprint

Adenosine Triphosphate
Pharmacology
Pinacidil
Muscle Cells
Diazoxide
Flavoproteins
Glyburide
Sulfonylurea Receptors
Kidney
KATP Channels
Membranes
Mitochondrial Membranes
mitochondrial K(ATP) channel
Mitochondria
Fluorescence
Rabbits
Pharmaceutical Preparations
5-hydroxydecanoic acid

ASJC Scopus subject areas

  • Pharmacology

Cite this

Pharmacological and histochemical distinctions between molecularly defined sarcolemmal K(ATP) channels and native cardiac mitochondrial K(ATP) channels. / Hu, Hai; Sato, Toshiaki; Seharaseyon, Jegatheesan; Liu, Yongge; Johns, David C.; O'Rourke, Brian; Marbán, Eduardo.

In: Molecular Pharmacology, Vol. 55, No. 6, 1999, p. 1000-1005.

Research output: Contribution to journalArticle

Hu, Hai ; Sato, Toshiaki ; Seharaseyon, Jegatheesan ; Liu, Yongge ; Johns, David C. ; O'Rourke, Brian ; Marbán, Eduardo. / Pharmacological and histochemical distinctions between molecularly defined sarcolemmal K(ATP) channels and native cardiac mitochondrial K(ATP) channels. In: Molecular Pharmacology. 1999 ; Vol. 55, No. 6. pp. 1000-1005.
@article{05bcf293ce784b20a0ba2ef14f31cdaf,
title = "Pharmacological and histochemical distinctions between molecularly defined sarcolemmal K(ATP) channels and native cardiac mitochondrial K(ATP) channels",
abstract = "A variety of direct and indirect techniques have revealed the existence of ATP-sensitive potassium (K(ATP)) channels in the inner membranes of mitochondria. The molecular identity of these mitochondrial K(ATP) (mitoK(ATP)) channels remains unclear. We used a pharmacological approach to distinguish mitoK(ATP) channels from classical, molecularly defined cardiac sarcolemmal K(ATP) (surfaceK(ATP)) channels encoded by the sulfonylurea receptor SUR2A and the pore-forming subunit K(ir)6.2. SUR2A and K(ir)6.2 were expressed in human embryonic kidney (HEK)293 cells, and their activities were measured by patch-clamp recordings of membrane current. SurfaceK(ATP) channels are activated potently by 100 μM pinacidil but only weakly by 100 μM diazoxide; in addition, they are blocked by 10 μM glibenclamide, but are insensitive to 500 μM 5-hydroxydecanoate. This pharmacology, which was confirmed with patch-clamp recordings in intact rabbit ventricular myocytes contrasts with that of mitoK(ATP) channels as indexed by flavoprotein oxidation. MitoK(ATP) channels in myocytes are activated equally by 100 μM diazoxide and 100 μM pinacidil. In contrast to its lack of effect on surfaceK(ATP) channels, 5-hydroxydecanoate is an effective blocker of mitoK(ATP) channels. Glibenclamide's effects on mitoK(ATP) channels are difficult to assess, because it independently activates flavoprotein fluorescence, consistent with a previously described primary uncoupling effect. Confocal imaging of the subcellular distribution of expressed fluorescent K(ir)6.2 in HEK cells and in myocytes revealed no targeting of mitochondrial membranes. The differences in drug sensitivity and subcellular localization indicate that mitoK(ATP) channels are distinct from surface N(ATP) channels at a molecular level.",
author = "Hai Hu and Toshiaki Sato and Jegatheesan Seharaseyon and Yongge Liu and Johns, {David C.} and Brian O'Rourke and Eduardo Marb{\'a}n",
year = "1999",
language = "English (US)",
volume = "55",
pages = "1000--1005",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Pharmacological and histochemical distinctions between molecularly defined sarcolemmal K(ATP) channels and native cardiac mitochondrial K(ATP) channels

AU - Hu, Hai

AU - Sato, Toshiaki

AU - Seharaseyon, Jegatheesan

AU - Liu, Yongge

AU - Johns, David C.

AU - O'Rourke, Brian

AU - Marbán, Eduardo

PY - 1999

Y1 - 1999

N2 - A variety of direct and indirect techniques have revealed the existence of ATP-sensitive potassium (K(ATP)) channels in the inner membranes of mitochondria. The molecular identity of these mitochondrial K(ATP) (mitoK(ATP)) channels remains unclear. We used a pharmacological approach to distinguish mitoK(ATP) channels from classical, molecularly defined cardiac sarcolemmal K(ATP) (surfaceK(ATP)) channels encoded by the sulfonylurea receptor SUR2A and the pore-forming subunit K(ir)6.2. SUR2A and K(ir)6.2 were expressed in human embryonic kidney (HEK)293 cells, and their activities were measured by patch-clamp recordings of membrane current. SurfaceK(ATP) channels are activated potently by 100 μM pinacidil but only weakly by 100 μM diazoxide; in addition, they are blocked by 10 μM glibenclamide, but are insensitive to 500 μM 5-hydroxydecanoate. This pharmacology, which was confirmed with patch-clamp recordings in intact rabbit ventricular myocytes contrasts with that of mitoK(ATP) channels as indexed by flavoprotein oxidation. MitoK(ATP) channels in myocytes are activated equally by 100 μM diazoxide and 100 μM pinacidil. In contrast to its lack of effect on surfaceK(ATP) channels, 5-hydroxydecanoate is an effective blocker of mitoK(ATP) channels. Glibenclamide's effects on mitoK(ATP) channels are difficult to assess, because it independently activates flavoprotein fluorescence, consistent with a previously described primary uncoupling effect. Confocal imaging of the subcellular distribution of expressed fluorescent K(ir)6.2 in HEK cells and in myocytes revealed no targeting of mitochondrial membranes. The differences in drug sensitivity and subcellular localization indicate that mitoK(ATP) channels are distinct from surface N(ATP) channels at a molecular level.

AB - A variety of direct and indirect techniques have revealed the existence of ATP-sensitive potassium (K(ATP)) channels in the inner membranes of mitochondria. The molecular identity of these mitochondrial K(ATP) (mitoK(ATP)) channels remains unclear. We used a pharmacological approach to distinguish mitoK(ATP) channels from classical, molecularly defined cardiac sarcolemmal K(ATP) (surfaceK(ATP)) channels encoded by the sulfonylurea receptor SUR2A and the pore-forming subunit K(ir)6.2. SUR2A and K(ir)6.2 were expressed in human embryonic kidney (HEK)293 cells, and their activities were measured by patch-clamp recordings of membrane current. SurfaceK(ATP) channels are activated potently by 100 μM pinacidil but only weakly by 100 μM diazoxide; in addition, they are blocked by 10 μM glibenclamide, but are insensitive to 500 μM 5-hydroxydecanoate. This pharmacology, which was confirmed with patch-clamp recordings in intact rabbit ventricular myocytes contrasts with that of mitoK(ATP) channels as indexed by flavoprotein oxidation. MitoK(ATP) channels in myocytes are activated equally by 100 μM diazoxide and 100 μM pinacidil. In contrast to its lack of effect on surfaceK(ATP) channels, 5-hydroxydecanoate is an effective blocker of mitoK(ATP) channels. Glibenclamide's effects on mitoK(ATP) channels are difficult to assess, because it independently activates flavoprotein fluorescence, consistent with a previously described primary uncoupling effect. Confocal imaging of the subcellular distribution of expressed fluorescent K(ir)6.2 in HEK cells and in myocytes revealed no targeting of mitochondrial membranes. The differences in drug sensitivity and subcellular localization indicate that mitoK(ATP) channels are distinct from surface N(ATP) channels at a molecular level.

UR - http://www.scopus.com/inward/record.url?scp=0033022308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033022308&partnerID=8YFLogxK

M3 - Article

VL - 55

SP - 1000

EP - 1005

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -